enGene Therapeutics Inc. (ENGN)
| Market Cap | 115.94M -67.7% |
| Revenue (ttm) | n/a |
| Net Income | -130.36M |
| EPS | -2.02 |
| Shares Out | 67.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 358,849 |
| Open | 1.760 |
| Previous Close | 1.780 |
| Day's Range | 1.720 - 1.810 |
| 52-Week Range | 1.400 - 12.250 |
| Beta | -0.28 |
| Analysts | Hold |
| Price Target | 3.29 (+90.17%) |
| Earnings Date | Sep 8, 2026 |
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ENGN stock is "Hold." The 12-month stock price target is $3.29, which is an increase of 90.17% from the latest price.
News
enGene Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Detalimogene, a non-viral gene therapy for NMIBC, demonstrates a 54% complete response rate, best-in-class tolerability, and workflow advantages for community practices. With $266 million in cash, pivotal data updates and regulatory filings are planned for late 2026, targeting approval in 2027.
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
enGene Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Detalimogene, a non-viral gene therapy for BCG-unresponsive NMIBC, is advancing toward a 2027 U.S. approval, supported by strong interim efficacy and safety data. The therapy is designed for easy adoption in community practices, with a commercial strategy targeting rapid uptake and broad reimbursement.
enGene Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Detalimogene voraplasmid is advancing toward FDA submission, with pivotal data maturing by year-end and strong interim efficacy and tolerability. Positioned for broad adoption in community urology practices, the product's ease of use and robust safety profile differentiate it, while a surfactant cohort aims to further enhance outcomes.
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for...
enGene Therapeutics Earnings release: Q3 2026
enGene Therapeutics released its Q3 2026 earnings on September 8, 2026, summarizing the period's financial results.
enGene Therapeutics Quarterly report: Q3 2026
enGene Therapeutics has published its Q3 2026 quarterly earnings report on September 8, 2026.
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will parti...
enGene Therapeutics Transcript: KOL event
The NMIBC market is expanding with increased sequencing and new therapies, especially for high-risk BCG-unresponsive patients. Detalimogene's non-viral profile, efficacy, and ease of use position it for strong adoption in community practices, with favorable pricing and reimbursement dynamics supporting its commercial potential.
enGene Therapeutics Slides: KOL event
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtu...
enGene announces changes to board, appoints Heffernan as Chairman
enGene (ENGN) Therapeutics announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid if approved. Det...
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of D...
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to ...
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
enGene downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded enGene (ENGN) to Underweight from Equal Weight without a price target The firm’s checks show reduced confidence from physicians that enGene’s LEGEND study will support signif...
enGene price target lowered to $4 from $6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on enGene (ENGN) to $4 from $6 and keeps a Buy rating on the shares following the Q2 report. The firm is waiting…
enGene implements plan to reduce workforce by 50%
In June, enGene (ENGN) implemented a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash. The Company has retained personnel and resources required to meet…
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for ...
enGene Therapeutics Earnings release: Q2 2026
enGene Therapeutics released its Q2 2026 earnings on June 15, 2026, summarizing the period's financial results.
enGene Therapeutics Quarterly report: Q2 2026
enGene Therapeutics has published its Q2 2026 quarterly earnings report on June 15, 2026.
enGene Therapeutics Transcript: AGM 2026
The meeting confirmed quorum, reviewed and approved the election of four directors until 2029, and reappointed KPMG LLP as auditor. All proposals passed with strong shareholder support, and no questions were raised on the main items.
enGene price target lowered to $2 from $9 at UBS
UBS lowered the firm’s price target on enGene (ENGN) to $2 from $9 and keeps a Neutral rating on the shares.
Leerink downgraded enGene to Market Perform following LEGEND update
As previously reported, Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a price target of $2, down from $19, following the “disappointing” LEGEND update as key debates around…
enGene downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded enGene (ENGN) to Perform from Outperform. The firm views updated interim data from the pivotal LEGEND cohort in BCG-unresponsive NMIBC as disappointing, and while the approval d...